Over 20% of cancer patients will suffer metastatic spread to the brain, and prognosis remains poor. Communication between tumour cells and host tissue is essential during metastasis, yet little is known of the processes underlying such interactions in the brain. Here we test the hypothesis that cross-talk between tumour cells and host brain cells, through tumour cell leukocyte function associated protein-1 (LFA-1), is critical in metastasis development. Temporal expression of LFA-1 and its major ligand intercellular adhesion molecule-1 (ICAM-1) was determined in two different mouse models of brain metastasis. Marked upregulation of both proteins was found, co-localising with astro...
Background: Brain metastasis is a major cause of cancer patient morbidity and mortality. The late s...
The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metast...
The majority of brain metastases originate from lung cancer, breast cancer and malignant melanoma. I...
Background Cellular adhesion molecules (CAMs), which are normally associated with leukocyte traffick...
Brain metastasis is a complication of increasing incidence in patients with breast cancer at advance...
Brain metastases treatments are usually based on surgery and radiation therapies with poor patient s...
Cellular and non-cellular components of the tumor microenvironment (TME) are emerging as key regulat...
Metastasis is the main cause of treatment failure and death in cancer patients. Metastasis of tumor ...
Brain metastasis leads to increased mortality and is a major site of relapse for several cancers, ye...
Fast growing malignant cancers represent a major therapeutic challenge. Basic cancer research has co...
Brain metastasis is a common complication of breast cancer patients with poor survival. Histological...
Brain metastasis is a frequent occurrence in cancer patients and carries a high mortality rate. The ...
The microenvironment has emerged as a promising source of novel therapeutic applications in experime...
Tumour metastasis to the brain is a complex process involving crosstalk between the circulating tumo...
The molecular basis for breast cancer metastasis to the brain is largely unknown(1,2). Brain relapse...
Background: Brain metastasis is a major cause of cancer patient morbidity and mortality. The late s...
The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metast...
The majority of brain metastases originate from lung cancer, breast cancer and malignant melanoma. I...
Background Cellular adhesion molecules (CAMs), which are normally associated with leukocyte traffick...
Brain metastasis is a complication of increasing incidence in patients with breast cancer at advance...
Brain metastases treatments are usually based on surgery and radiation therapies with poor patient s...
Cellular and non-cellular components of the tumor microenvironment (TME) are emerging as key regulat...
Metastasis is the main cause of treatment failure and death in cancer patients. Metastasis of tumor ...
Brain metastasis leads to increased mortality and is a major site of relapse for several cancers, ye...
Fast growing malignant cancers represent a major therapeutic challenge. Basic cancer research has co...
Brain metastasis is a common complication of breast cancer patients with poor survival. Histological...
Brain metastasis is a frequent occurrence in cancer patients and carries a high mortality rate. The ...
The microenvironment has emerged as a promising source of novel therapeutic applications in experime...
Tumour metastasis to the brain is a complex process involving crosstalk between the circulating tumo...
The molecular basis for breast cancer metastasis to the brain is largely unknown(1,2). Brain relapse...
Background: Brain metastasis is a major cause of cancer patient morbidity and mortality. The late s...
The heterogeneity of tumor infiltrating lymphocytes (TILs) is not well characterized in brain metast...
The majority of brain metastases originate from lung cancer, breast cancer and malignant melanoma. I...